Concepedia

Shu Li

SL

Statistics

Publications

3

Citations

443

H-Index

3

Active since

2018

Affiliations

Second Affiliated Hospital of Zhejiang University(Current)

Zhejiang University

Shu Li is an author at Second Affiliated Hospital of Zhejiang University specializing in medicine, immunology, and immunotherapy.

ORCID

Publications per year

2018–2019

3

Publications

3

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Kristian Reich, April W. Armstrong, Richard G. Langley et al. · The Lancet · 2019 · 376 citations

, , +12

Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL–NKG2D Axis

Zhan Wang, Zenan Wang, Shu Li et al. · Frontiers in Immunology · 2018 · 36 citations · Full text

, , +17

Prognostic factors for survival among patients with primary bone sarcomas of small bones

Zhan Wang, Shu Li, Yong Li et al. · Cancer Management and Research · 2018 · 31 citations · Full text

, , +17

1–3 of 3